Globus Medical (GMED) analyst forecast and price target
Analyst forecast
Consensus of 17 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Overweight | $99.00 from $103.00 | Aug 7, 2026 |
| UBS | Initiated Coverage | Neutral | $82.00 | Jul 28, 2026 |
| Truist Securities | Maintained | Buy | $100.00 from $115.00 | Jul 16, 2026 |
| RBC Capital | Maintained | Outperform | $115.00 from $120.00 | Jul 13, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $94.00 | Jul 9, 2026 |
| Stifel | Maintained | Hold | $80.00 from $95.00 | Jul 8, 2026 |
| Piper Sandler | Maintained | Overweight | $100.00 from $115.00 | Jun 15, 2026 |
| Needham | Maintained | Buy | $117.00 from $114.00 | May 8, 2026 |
| Wells Fargo | Maintained | Overweight | $103.00 from $104.00 | May 8, 2026 |
| RBC Capital | Maintained | Outperform | $120.00 from $115.00 | May 8, 2026 |
| Wells Fargo | Maintained | Overweight | $104.00 from $98.00 | Feb 26, 2026 |
| Needham | Maintained | Buy | $114.00 from $112.00 | Feb 25, 2026 |
| Barclays | Maintained | Overweight | $123.00 from $118.00 | Feb 25, 2026 |
| Needham | Upgraded | Hold → Buy | $112.00 | Jan 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $112.00 from $105.00 | Jan 9, 2026 |
| Piper Sandler | Maintained | Overweight | $115.00 from $90.00 | Jan 8, 2026 |
| RBC Capital | Maintained | Outperform | $100.00 from $92.00 | Dec 17, 2025 |
| Canaccord Genuity | Maintained | Buy | $105.00 from $90.00 | Dec 17, 2025 |
| Freedom Capital Markets | Initiated Coverage | Hold | $87.00 | Dec 17, 2025 |
| Morgan Stanley | Maintained | Overweight | $100.00 from $70.00 | Dec 2, 2025 |
Frequently asked questions
What is the price target for GMED stock?
The average 12-month analyst price target for Globus Medical (GMED) is $95.71, with a high estimate of $115.00 and a low of $80.00, across 7 analysts.
Is GMED a buy, sell, or hold?
Analysts covering Globus Medical currently average a Buy rating: 11 buy, 6 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for GMED?
The average price target of $95.71 implies 17.95% upside from the last price of $81.15.
What is the latest analyst rating on GMED?
On Aug 7, 2026, Wells Fargo maintained Globus Medical at Overweight with a price target of $99.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.